This article was originally published in The Gray Sheet
American Medical Association will pay Sunbeam $7.9 mil. in damages and $2 mil. for expenses under a settlement agreement announced July 31. The settlement resolves a September 1997 Sunbeam suit designed to hold AMA to the terms of a five-year marketing/educational agreement, which included the use of the AMA symbol on over-the-counter Sunbeam health care products in exchange for inclusion of AMA educational materials with the products ("The Gray Sheet" Sept. 15, 1997, In Brief). AMA put the agreement on hold after concerns were raised that the use of the association's symbol might be perceived as a product endorsement
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.